For Swiss drug and diagnostics giant Roche (Nasdaq:RHHBY), the hits just keep on coming. Already bruised by setbacks in the Avastin franchise, Roche announced Friday morning that the FDA rejected an accelerated approval application for T-DM1, a potentially major drug for metastatic breast cancer. As the originator of the technology behind the drug and Roche's partner, ImmunoGen (Nasdaq:IMGN) will also suffer for this surprising FDA decision.

IN PICTURES: 9 Simple Investing Ratios You Need To Know

Precision Munition for Resistant Patients
In very simplified terms, T-DM1 is a derivative of Roche's successful Herceptin drug. ImmunoGen found a way to add a cell-killing compound (DM1) to the HER2 binding antibody trastuzumab that is the active component of Herceptin. What this means in practice is that T-DM1 hones in on the HER2+ cancer cells and delivers a lethal dose, while sparing the sort of system-wide toxicity that so often limits powerful drugs. In early stage studies this drug has shown progression-free survival of five to seven months and Roche had been talking about this drug as a $2-$5 billion/year opportunity.

The Timeline Slides Back
Roche had hoped to achieve an accelerated approval from the FDA that would have likely meant approval in early 2011. The FDA allows these approvals in circumstances where there are serious diseases with minimal options. Although that would certainly seem to apply to third-line metastatic breast cancer (that is, breast cancer that has spread beyond the breast and showed resistance to two prior drugs), the FDA ruled in this case that the patients in Roche's study groups had not exhausted all available options.

Regardless of whether the FDA is being overly literal or not, there is little than Roche can do about it. Now, instead of an early 2011 approval, Roche is looking at a filing in mid-2012, and a possible follow-on filing for T-DM1 as a front-line therapy in 2014. Given the normal FDA review timeline, that means a likely delay of two and a half years. (For related reading, see Measuring The Medicine Makers.)

Where Do They Go Now?
This is clearly a significant setback for ImmunoGen. T-DM1 is the company's only late-stage candidate, and it will be years before the company's other pipeline candidates, IMGN901 and earlier candidates partnered with Sanofi-Aventis (NYSE:SNY) and Biogen Idec (Nasdaq:BIIB), get close to the market.

Moreover, ImmunoGen could certainly have used the milestone payment from Roche that is tied to approval, as well as the royalties from actual sales. With about $110 million in cash and a $10 million quarterly burn rate, ImmunoGen could find itself cash-constrained without additional milestones or financing.

For Roche too, this is a major setback. Roche has been struggling to generate enthusiasm lately, as investors increasingly seem to perceive it as a company with low earnings growth potential and relatively near-term risk of biologics competition from Teva (Nasdaq:TEVA) and Mylan (NYSE:MYL). As a valuable line extension of the Herceptin franchise, this delay on T-DM1 does the company no favors in terms of trying to get investors on board with better near-term expectations.

The Bottom Line
Figuring on a two-and-a-half year delay in T-DM1 (but eventual approval all the same), this news would seem to reduce the fair value of ImmunoGen by about $2 per share. Since the market has driven the stock down by $3, patient risk-tolerant investors may want to take a look - the data on this drug still looks good, and the real damage from this announcement is a time value of money question.

For Roche, the impact is likely to be more severe on perception than financials. T-DM1 should be a lucrative product for the company, but Roche is large enough that this delay is not a serious wound. Still, the seemingly constant stream of bad news is taking a toll on perception and weighing heavily on the stock. Roche shares look quite cheap for the long haul, but will likely be frustrating to investors who are not patient long-term value mavens. (For more, see Big Pharma's Big Problem.)

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

Related Articles
  1. Investing News

    Bank Stocks: Time to Buy or Avoid? (WFC, JPM, C)

    Bank stocks have been pounded. Is this the right time to buy or should they be avoided?
  2. Stock Analysis

    Why the Bullish Are Turning Bearish

    Banks are reducing their targets for the S&P 500 for 2016. Here's why.
  3. Stock Analysis

    How to Find Quality Stocks Amid the Wreckage

    Finding companies with good earnings and hitting on all cylinders in this environment, although possible, is not easy.
  4. Stock Analysis

    Analyzing Sirius XM's Return on Equity (ROE) (SIRI)

    Learn more about the Sirius XM's overall 2015 performance, return on equity performance and future predictions for the company's ROE in 2016 and beyond.
  5. Stock Analysis

    Will Virtusa Corporation's Stock Keep Chugging in 2016? (VRTU)

    Read a thorough review and analysis of Virtusa Corporation's stock looking to project how well the stock is likely to perform for investors in 2016.
  6. Stock Analysis

    Analyzing Porter's Five Forces on JPMorgan Chase (JPM)

    Examine the major money-center bank holding firm, JPMorgan Chase & Company, from the perspective of Porter's five forces model for industry analysis.
  7. Investing News

    What You Can Learn from Carl Icahn's Mistakes

    Carl Icahn has been a stellar performer in the investment world for decades, but following his lead these days could be dangerous.
  8. Stock Analysis

    Analyzing Dish Network's Return on Equity (ROE) (DISH, TWC)

    Analyze Dish Network's return on equity (ROE), understand why it has vacillated so greatly in recent years and learn what factors are influencing it.
  9. Fundamental Analysis

    5 Must-Have Metrics For Value Investors

    Focusing on certain fundamental metrics is the best way for value investors to cash in gains. Here are the most important metrics to know.
  10. Stock Analysis

    Analyzing Altria's Return on Equity (ROE) (MO)

    Learn about Altria Group's return on equity (ROE) and analyze net profit margin, asset turnover and financial leverage to determine what is causing its high ROE.
RELATED FAQS
  1. When does a growth stock turn into a value opportunity?

    A growth stock turns into a value opportunity when it trades at a reasonable multiple of the company's earnings per share ... Read Full Answer >>
  2. What is the formula for calculating EBITDA?

    When analyzing financial fitness, corporate accountants and investors alike closely examine a company's financial statements ... Read Full Answer >>
  3. How do I calculate the P/E ratio of a company?

    The price-earnings ratio (P/E ratio) is a valuation measure that compares the level of stock prices to the level of corporate ... Read Full Answer >>
  4. How do you calculate return on equity (ROE)?

    Return on equity (ROE) is a ratio that provides investors insight into how efficiently a company (or more specifically, its ... Read Full Answer >>
  5. How do you calculate working capital?

    Working capital represents the difference between a firm’s current assets and current liabilities. The challenge can be determining ... Read Full Answer >>
  6. What is the formula for calculating the current ratio?

    The current ratio is a financial ratio that investors and analysts use to examine the liquidity of a company and its ability ... Read Full Answer >>
COMPANIES IN THIS ARTICLE
Trading Center